Pharmacoeconomic analysis of vemurafenib in treatment of inoperable or metastatic melanoma in patients with BRAF V600 mutation

Autor:	A. A. Kurylev, M. Proskurin, I. A. Vilyum, Yu.E. Balykina, A.S. Kolbin
Rok vydání:	2015
Předmět:	Oncology medicine.medical_specialty Metastatic melanoma business.industry Melanoma medicine.disease Dermatology Internal medicine Mutation (genetic algorithm) medicine BRAF V600 Mutation In patient business Vemurafenib neoplasms medicine.drug
Zdroj:	Pharmacoeconomics: theory and practice. 3:22-27
ISSN:	2312-2862
Popis:	2i/v every 3 weeks. Mathematical modelling underlies this study. As a result it has been demonstrated that the use of vemurafenib strategy in treatment of metastatic melanoma in patients with BRAF V600 mutation had better progression-free survival (PFS) rate throughout the entire modelling horizon. The use of vemurafenib in treatment of metastatic and inoperable melanoma in patients with BRAF V600 mutation is economically advisable taking into account the data on effectiveness (PFS). The use of vemurafenib in patients with BRAF V600 mutation is an absolutely innovative medical technology which currently does not have any alternative. Vemurafenib may be indicated for inclusion in reimbursement lists for treatment of patients with this mutation.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4e1e5303fb7e06df7e8b1e186c2bc94d https://doi.org/10.30809/phe.4.2015.4 Zobrazit plný text záznamu